论文部分内容阅读
目的观察急性冠脉综合征(ACS)患者血清高迁移率族蛋白B1(HMGB1)水平和超敏C反应蛋白(hs-CRP)水平变化,探讨其与冠状动脉病变程度及短期预后的关系。方法选择ACS患者共57例,其中急性心肌梗死(AMI)30例,不稳定型心绞痛(UA)27例;单支病变33例,多支病变24例。同时选择26例健康对照组。采用酶联免疫吸附试验(ELISA)法测定所有受试者血清HMGB1;并同时测定hs-CRP。结果 ACS组患者血清HMGB1及hs-CRP浓度均高于健康对照组(P<0.05),AMI与UA两组间HMGB1浓度无明显统计学意义(P>0.05);ACS组患者血清HMGB1与hs-CRP水平呈正相关(γ=0.343,P<0.05);多支病变组HMGB1浓度显著高于单支病变组(P<0.05)。发生MACE的患者HMGB1及hs-CRP浓度均显著高于未发生MACE患者,(P<0.05)。结论 1、ACS组患者血清HMGB1水平及hs-CRP水平均显著升高。2、ACS组患者血清HMGB1水平与hs-CRP水平呈正相关。3、ACS患者多支病变组血清HMGB1水平显著高于单支病变组。4、血清HMGB1水平及hs-CRP水平可能是预测AMI组患者MACE的危险因素的指标。
Objective To observe the changes of serum high mobility group box-1 (HMGB1) and hs-CRP levels in patients with acute coronary syndrome (ACS) and to investigate their relationship with the degree of coronary artery disease and short-term prognosis. Methods Fifty-seven ACS patients were selected, including 30 AMI patients and 27 unstable angina pectoris (UA) patients. Among them, 33 had single-vessel disease and 24 had multiple-vessel disease. At the same time select 26 healthy control group. Serum levels of HMGB1 were measured by enzyme linked immunosorbent assay (ELISA), and hs-CRP was also determined. Results Serum levels of HMGB1 and hs-CRP in ACS patients were significantly higher than those in healthy controls (P <0.05). There was no significant difference in serum HMGB1 levels between ACS patients and UA patients (P> 0.05) CRP levels were positively correlated (γ = 0.343, P <0.05). The HMGB1 concentration in multi-vessel disease group was significantly higher than that in single vessel disease group (P <0.05). The levels of HMGB1 and hs-CRP in patients with MACE were significantly higher than those without MACE (P <0.05). Conclusion 1, Serum HMGB1 levels and hs-CRP levels in ACS patients were significantly increased. Serum levels of HMGB1 in patients with ACS were positively correlated with hs-CRP levels. Serum levels of HMGB1 in ACS patients with multi-vessel disease were significantly higher than those in single vessel disease group. Serum levels of HMGB1 and hs-CRP may be the predictors of MACE risk in patients with AMI.